PHILADELPHIA, Jan. 8, 2025 /PRNewswire/ — Today, Dr. Jim Wilson, President and CEO of GEMMA Biotherapeutics (“GEMMABio”) commented on Solid Bioscience’s announcement of clearance by the Food and Drug Administration for its Investigational New Drug (IND) to treat Friedreich’s ataxia (FA):…

CAMBRIDGE, England and SAN DIEGO, Jan. 8, 2025 /PRNewswire/ — DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its “First in Human” Coronavirus vaccine trial, to announce its new…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.